Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 4/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962561 | 1.00 | SYK (0.55) | SYKPDE4DCHEK1ARSSTR4 | |
| SCHEMBL1962558 | 1.00 | SYK (0.55) | SYKPDE4DCHEK1ARSSTR4 | |
| SCHEMBL248302 | 0.92 | SYK (0.65) | SYKCHEK1ARSSTR4MRGPRX4 | |
| SCHEMBL1962810 | 0.83 | TRPC6 (0.44) | PDE4DCHEK1ARALKIKBKE | |
| SCHEMBL1965826 | 0.83 | TRPC6 (0.44) | PDE4DCHEK1ARALKIKBKE | |
| SCHEMBL3747459 | 0.83 | TRPC6 (0.44) | PDE4DCHEK1ARALKIKBKE | |
| SCHEMBL15801283 | 0.80 | SYK (0.84) | SYKPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL12180311 | 0.80 | SYK (0.84) | SYKPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL27077048 | 0.80 | SYK (0.59) | SYKPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL12391611 | 0.80 | CHEK1 (0.45) | SYKPDE4DCHEK1ALKIKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509424-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | S1PR3, S1PR1, S1PR2 | SYK 939/4885PDE4D 106/4885CHEK1 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.